These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20191497)

  • 21. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries.
    Kimsey L; Weissman JS; Patel A; Drew A; Koehlmoos T; Sparks JA
    Semin Arthritis Rheum; 2019 Apr; 48(5):821-827. PubMed ID: 30190154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
    Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
    Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort.
    Kristensen LE; Bliddal H; Christensen R; Karlsson JA; Gülfe A; Saxne T; Geborek P
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):173-9. PubMed ID: 23982986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
    Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
    JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids.
    George MD; Baker JF; Wallace B; Chen L; Wu Q; Xie F; Yun H; Curtis JR
    Arthritis Care Res (Hoboken); 2021 Nov; 73(11):1597-1605. PubMed ID: 32702188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of anti-TNF-α vs. DMARDs on fatigue in rheumatoid arthritis patients.
    van Hoogmoed D; Fransen J; Repping-Wuts H; Spee L; Bleijenberg G; van Riel PL
    Scand J Rheumatol; 2013; 42(1):15-9. PubMed ID: 22992002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
    Finckh A; Dehler S; Gabay C;
    Ann Rheum Dis; 2009 Jan; 68(1):33-9. PubMed ID: 18230627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
    Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
    JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis -- results from the DANBIO registry.
    Jawaheer D; Olsen J; Hetland ML
    J Rheumatol; 2012 Jan; 39(1):46-53. PubMed ID: 22089458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
    Harrison MJ; Dixon WG; Watson KD; King Y; Groves R; Hyrich KL; Symmons DP; ;
    Ann Rheum Dis; 2009 Feb; 68(2):209-15. PubMed ID: 18385277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
    McBride S; Sarsour K; White LA; Nelson DR; Chawla AJ; Johnston JA
    J Rheumatol; 2011 Oct; 38(10):2141-9. PubMed ID: 21844154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fatigue in rheumatoid arthritis reflects pain, not disease activity.
    Pollard LC; Choy EH; Gonzalez J; Khoshaba B; Scott DL
    Rheumatology (Oxford); 2006 Jul; 45(7):885-9. PubMed ID: 16449363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.
    Hyrich KL; Watson KD; Lunt M; Symmons DP;
    Rheumatology (Oxford); 2011 Jan; 50(1):117-23. PubMed ID: 20671021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
    Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent trends in use of nonbiologic DMARDs and evaluation of their continuation rates in single and dual combination therapies in rheumatoid arthritis patients in Japan.
    Ogasawara M; Kageyama M; Kusaoi M; Onuma S; Kon T; Sekiya F; Sugimoto K; Matsudaira R; Matsushita M; Tada K; Kempe K; Yamaji K; Tamura N; Takasaki Y
    Mod Rheumatol; 2012 Nov; 22(6):831-6. PubMed ID: 22350576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort.
    Moura CS; Schieir O; Valois MF; Thorne C; Bartlett SJ; Pope JE; Hitchon CA; Boire G; Haraoui B; Hazlewood GS; Keystone EC; Tin D; Bykerk VP; Bernatsky S;
    Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1104-1111. PubMed ID: 31112011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.